Evidence map›Paper›PMID 42703456›Full record

ArticleJournal of gastrointestinal oncology2026

DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation.

Revathi Ravella, Wini Zambare, Diana Roth O'Brien, Paul B Romesser

Abstract readLetterComment
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Revathi RavellaDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wini ZambareDepartment of Surgery, Colorectal Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Diana Roth O'BrienDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul B RomesserDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0001-8268-2903

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SURGICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009501 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Babak J Mehrara · 1985 to 2026
$7.7M
Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal CancerR37CA304010 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Paul Bernard Romesser · 2025 to 2026
$1.5M
Investigating the contribution of cellular senescence to the efficacy of radiation therapy.K08CA255574 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROMESSER, PAUL BERNARD · 2021 to 2025
$1.2M
NCI NIH HHS K08 CA255574NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA304010NCI NIH HHS T32 CA009501
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42703456
PMCPMC13546592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.